# A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)

> **NCT01725256** · PHASE2 · TERMINATED · sponsor: **Aires Pharmaceuticals, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** AIR001 (sodium nitrite inhalation solution)

## Key facts

- **NCT ID:** NCT01725256
- **Lead sponsor:** Aires Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Terminated early dt to acquisition of Sponsor and change in corporate priorities
- **Last updated:** 2014-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01725256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01725256, "A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01725256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*